TROIA, ROSSELLA
TROIA, ROSSELLA
BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma
2021-01-01 Oliva S.; De Paoli L.; Ruggeri M.; Caltagirone S.; Troia R.; Oddolo D.; D'Agostino M.; Gilestro M.; Mina R.; Saraci E.; Margiotta Casaluci G.; Genuardi E.; Bringhen S.; Boccadoro M.; Omede P.
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
2020-01-01 Cavo M.; Gay F.; Beksac M.; Pantani L.; Petrucci M.T.; Dimopoulos M.A.; Dozza L.; van der Holt B.; Zweegman S.; Oliva S.; van der Velden V.H.J.; Zamagni E.; Palumbo G.A.; Patriarca F.; Montefusco V.; Galli M.; Maisnar V.; Gamberi B.; Hansson M.; Belotti A.; Pour L.; Ypma P.; Grasso M.; Croockewit A.; Ballanti S.; Offidani M.; Vincelli I.D.; Zambello R.; Liberati A.M.; Andersen N.F.; Broijl A.; Troia R.; Pascarella A.; Benevolo G.; Levin M.-D.; Bos G.; Ludwig H.; Aquino S.; Morelli A.M.; Wu K.L.; Boersma R.; Hajek R.; Durian M.; von dem Borne P.A.; Caravita di Toritto T.; Zander T.; Specchia G.; Waage A.; Gimsing P.; Mellqvist U.-H.; van Marwijk Kooy M.; Minnema M.; Mandigers C.; Cafro A.M.; Palmas A.; Carvalho S.; Spencer A.; Boccadoro M.; Sonneveld P.
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis
2017-01-01 Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M.
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma
2014-01-01 Bringhen S.; Gay F.; Donato F.; Troia R.; Mina R.; Palumbo A.
Melphalan hydrochloride for the treatment of multiple myeloma
2017-01-01 Esma, Fabrizio; Salvini, Marco; Troia, Rossella; Boccadoro, Mario; Larocca, Alessandra; Pautasso, Chiara*
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
2021-01-01 Oliva, Stefania; Hofste op Bruinink, Davine; Rihova, Lucie; D'Agostino, Mattia; Pantani, Lucia; Capra, Andrea; van der Holt, Bronno; Troia, Rossella; Petrucci, Maria Teresa; Villanova, Tania; Vsianska, Pavla; Jugooa, Romana; Brandt-Hagens, Claudia; Gilestro, Milena; Offidani, Massimo; Ribolla, Rossella; Galli, Monica; Hajek, Roman; Gay, Francesca; Cavo, Michele; Omedé, Paola; van der Velden, Vincent H J; Boccadoro, Mario; Sonneveld, Pieter
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
2019-01-01 Gambella M.; Omede P.; Spada S.; Muccio V.E.; Gilestro M.; Saraci E.; Grammatico S.; Larocca A.; Conticello C.; Bernardini A.; Gamberi B.; Troia R.; Liberati A.M.; Offidani M.; Rocci A.; Palumbo A.; Cavo M.; Sonneveld P.; Boccadoro M.; Oliva S.
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma
2014-01-01 Donato F.; Gay F.; Bringhen S.; Troia R.; Palumbo A.
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
2018-01-01 Bringhen S.; Mina R.; Cafro A.M.; Liberati A.M.; Spada S.; Belotti A.; Gaidano G.; Patriarca F.; Troia R.; Fanin R.; De Paoli L.; Rossi G.; Lombardo A.; Bertazzoni P.; Palumbo A.; Sonneveld P.; Boccadoro M.
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma
2018-01-01 Salvini, Marco; Troia, Rossella; Giudice, Davide; Pautasso, Chiara; Boccadoro, Mario; Larocca, Alessandra*
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma
2013-01-01 Gay F.; Mina R.; Troia R.; Bringhen S.
Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma
2018-01-01 Oliva S.; Troia R.; D'Agostino M.; Boccadoro M.; Gay F.
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma
2017-01-01 Offidani, Massimo; Corvatta, Laura; Bringhen, Sara; Gentili, Silvia; Troia, Rossella; Maracci, Laura; Larocca, Alessandra; Gay, Francesca; Leoni, Pietro; Boccadoro, Mario
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma | 2021 | Oliva S.; De Paoli L.; Ruggeri M.; Caltagirone S.; Troia R.; Oddolo D.; D'Agostino M.; Gilestro M.; Mina R.; Saraci E.; Margiotta Casaluci G.; Genuardi E.; Bringhen S.; Boccadoro M.; Omede P. | |
| Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study | 2020 | Cavo M.; Gay F.; Beksac M.; Pantani L.; Petrucci M.T.; Dimopoulos M.A.; Dozza L.; van der Holt B.; Zweegman S.; Oliva S.; van der Velden V.H.J.; Zamagni E.; Palumbo G.A.; Patriarca F.; Montefusco V.; Galli M.; Maisnar V.; Gamberi B.; Hansson M.; Belotti A.; Pour L.; Ypma P.; Grasso M.; Croockewit A.; Ballanti S.; Offidani M.; Vincelli I.D.; Zambello R.; Liberati A.M.; Andersen N.F.; Broijl A.; Troia R.; Pascarella A.; Benevolo G.; Levin M.-D.; Bos G.; Ludwig H.; Aquino S.; Morelli A.M.; Wu K.L.; Boersma R.; Hajek R.; Durian M.; von dem Borne P.A.; Caravita di Toritto T.; Zander T.; Specchia G.; Waage A.; Gimsing P.; Mellqvist U.-H.; van Marwijk Kooy M.; Minnema M.; Mandigers C.; Cafro A.M.; Palmas A.; Carvalho S.; Spencer A.; Boccadoro M.; Sonneveld P. | |
| Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis | 2017 | Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M. | |
| Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma | 2014 | Bringhen S.; Gay F.; Donato F.; Troia R.; Mina R.; Palumbo A. | |
| Melphalan hydrochloride for the treatment of multiple myeloma | 2017 | Esma, Fabrizio; Salvini, Marco; Troia, Rossella; Boccadoro, Mario; Larocca, Alessandra; Pautasso, Chiara* | |
| Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial | 2021 | Oliva, Stefania; Hofste op Bruinink, Davine; Rihova, Lucie; D'Agostino, Mattia; Pantani, Lucia; Capra, Andrea; van der Holt, Bronno; Troia, Rossella; Petrucci, Maria Teresa; Villanova, Tania; Vsianska, Pavla; Jugooa, Romana; Brandt-Hagens, Claudia; Gilestro, Milena; Offidani, Massimo; Ribolla, Rossella; Galli, Monica; Hajek, Roman; Gay, Francesca; Cavo, Michele; Omedé, Paola; van der Velden, Vincent H J; Boccadoro, Mario; Sonneveld, Pieter | |
| Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis | 2019 | Gambella M.; Omede P.; Spada S.; Muccio V.E.; Gilestro M.; Saraci E.; Grammatico S.; Larocca A.; Conticello C.; Bernardini A.; Gamberi B.; Troia R.; Liberati A.M.; Offidani M.; Rocci A.; Palumbo A.; Cavo M.; Sonneveld P.; Boccadoro M.; Oliva S. | |
| Monoclonal antibodies currently in Phase II and III trials for multiple myeloma | 2014 | Donato F.; Gay F.; Bringhen S.; Troia R.; Palumbo A. | |
| Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study | 2018 | Bringhen S.; Mina R.; Cafro A.M.; Liberati A.M.; Spada S.; Belotti A.; Gaidano G.; Patriarca F.; Troia R.; Fanin R.; De Paoli L.; Rossi G.; Lombardo A.; Bertazzoni P.; Palumbo A.; Sonneveld P.; Boccadoro M. | |
| Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma | 2018 | Salvini, Marco; Troia, Rossella; Giudice, Davide; Pautasso, Chiara; Boccadoro, Mario; Larocca, Alessandra* | |
| Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma | 2013 | Gay F.; Mina R.; Troia R.; Bringhen S. | |
| Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma | 2018 | Oliva S.; Troia R.; D'Agostino M.; Boccadoro M.; Gay F. | |
| Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma | 2017 | Offidani, Massimo; Corvatta, Laura; Bringhen, Sara; Gentili, Silvia; Troia, Rossella; Maracci, Laura; Larocca, Alessandra; Gay, Francesca; Leoni, Pietro; Boccadoro, Mario |